McCormick Stock: Institutional Doubt Meets Strategic Expansion

McCormick & Company finds itself at a critical juncture. While the spice giant executes a strategic acquisition in Mexico to fuel its growth engine, major institutional investors are displaying increasing caution. This divergence of views unfolds against a backdrop of mixed analyst sentiment and a share price hovering near its annual low, raising questions about the consumer staples company’s near-term trajectory.

Strategic Acquisition to Boost Regional Presence

A significant development in McCormick’s growth strategy is its move to increase ownership in its Mexican joint venture with Grupo Herdez from 50% to 75%. This $750 million transaction, anticipated to close in early 2026, is projected to contribute approximately 1% to earnings per share (EPS) in the 2026 fiscal year. The deal, valued at 12 times the venture’s projected 2025 EBITDA, has been viewed favorably by some on Wall Street. TD Cowen analysts endorsed the move as “good capital deployment,” reiterating an Outperform rating and an $82 price target, citing the enhanced growth prospects in the region.

Major Investors Adopt a Cautious Stance

Contrasting this strategic optimism, recent SEC filings reveal a wave of skepticism among professional money managers. American Century Companies Inc. reduced its McCormick holding by 5.0% in the first quarter, divesting 2,106 shares. This activity is indicative of a broader, more prudent stance being adopted by institutional investors, suggesting active portfolio management due to uncertainties surrounding the company’s short-term outlook.

A Clear Divide Among Market Analysts

The analyst community is sharply divided on the stock’s prospects. The contrasting opinions highlight the uncertainty. UBS downgraded its price target to $79, pointing to challenges within the Flavor Solutions segment and ongoing pricing dynamics. In a starkly different assessment, JPMorgan upgraded McCormick from Underweight to Overweight, lifting its price target to $83. The firm perceives the recent share price weakness as an attractive entry point for investors. The consensus price target stands at $84.14, implying a potential upside of roughly 20% from current levels.

Should investors sell immediately? Or is it worth buying McCormick?

Strong Operational Results Versus Stock Performance

The disconnect between corporate performance and market valuation is notable. McCormick’s stock is currently trading just above its 52-week low of $69.08 and has declined 10.32% over the past twelve months. This performance comes despite a solid second-quarter 2025 report. The company posted adjusted earnings per share of $0.69, surpassing the $0.66 consensus estimate. Revenue of $1.66 billion was in line with forecasts, supported by 2% organic sales growth and a 10% year-over-year increase in adjusted operating income.

However, data from Finviz.com classifies the stock as a sell, highlighting concerns over disappointing organic sales growth across the past two years and minimal annual EPS growth of just 2% over the last three-year period. Furthermore, the company has seen an increase in capital intensity and a 4.8-percentage-point contraction in its free-cash-flow margin.

The central question remains whether McCormick’s strategic moves in Mexico and its underlying operational strength can ultimately overcome investor skepticism. With conflicting signals from major institutions and research analysts, the stock presents a compelling case for market observers.